Skip to Content

Ceftriaxone / lidocaine Disease Interactions

There are 8 disease interactions with ceftriaxone / lidocaine:

Major

Antiarrhythmics (Includes Ceftriaxone/lidocaine) ↔ Cardiovascular Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Congestive Heart Failure, Hypotension

Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF). Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk. Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF. Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.

References

  1. Halkin H, Meffin P, Melmon KL, Rowland M "Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite." Clin Pharmacol Ther 17 (1975): 669-76
  2. Crouthamel WG "The effect of congestive heart failure on quinidine pharmacokinetics." Am Heart J 90 (1975): 335-9
  3. "Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
View all 17 references
Major

Antiarrhythmics (Includes Ceftriaxone/lidocaine) ↔ Proarrhythmic Effects

Severe Potential Hazard, High plausibility

Applies to: Arrhythmias

Antiarrhythmic agents can induce or worsen ventricular arrhythmias. Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients. Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias. Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias. Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias. Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.

References

  1. "Product Information. Tambocor (flecainide)." 3M Pharmaceuticals, St. Paul, MN.
  2. "Product Information. Adenocard (adenosine)." Fujisawa, Deerfield, IL.
  3. Andrivet P, Beaslay V, Canh VD "Torsades de pointe with flecainide-amiodarone therapy." Intensive Care Med 16 (1990): 342-3
View all 62 references
Moderate

Antiarrhythmics (Includes Ceftriaxone/lidocaine) ↔ Electrolyte Imbalance

Moderate Potential Hazard, High plausibility

Applies to: Hypokalemia, Hyperkalemia, Magnesium Imbalance

Electrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents. Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents. In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsades de pointes. Hyperkalemia can potentiate the toxic effects of antiarrhythmic agents. Electrolyte imbalance should be corrected prior to initiating antiarrhythmic therapy. Clinical monitoring of cardiac function and electrolyte concentrations is recommended.

References

  1. "Product Information. Tonocard (tocainide)." Merck & Co, Inc, West Point, PA.
  2. "Product Information. Norpace (disopyramide)." Searle, Skokie, IL.
  3. "Product Information. Quinidex (quinidine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
View all 13 references
Moderate

Antibiotics (Includes Ceftriaxone/lidocaine) ↔ Colitis

Moderate Potential Hazard, Moderate plausibility

Applies to: Colitis/Enteritis (Noninfectious)

Pseudomembranous colitis has been reported with most antibacterial agents and may range in severity from mild to life-threatening, with an onset of up to two months following cessation of therapy. Antibiotic therapy can alter the normal flora of the colon and permit overgrowth of Clostridium difficile, whose toxin is believed to be a primary cause of antibiotic- associated colitis. The colitis is usually characterized by severe, persistent diarrhea and severe abdominal cramps, and may be associated with the passage of blood and mucus. The most common culprits are clindamycin, lincomycin, the aminopenicillins (amoxicillin, ampicillin), and the cephalosporins. Therapy with broad-spectrum antibiotics and other agents with significant antibacterial activity should be administered cautiously in patients with a history of gastrointestinal diseases, particularly colitis. There is some evidence that pseudomembranous colitis, if it occurs, may run a more severe course in these patients and that it may be associated with flares in their underlying disease activity. The offending antibiotic(s) should be discontinued if significant diarrhea occurs during therapy. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically. A large bowel endoscopy may be considered to establish a definitive diagnosis in cases of severe diarrhea.

References

  1. Moriarty HJ, Scobie BA "Pseudomembranous colitis in a patient on rifampicin and ethambutol." N Z Med J 04/23/80 (1980): 294-5
  2. Thomas E, Mehta JB "Pseudomembranous colitis due to oxacillin therapy." South Med J 77 (1984): 532-3
  3. Harmon T, Burkhart G, Applebaum H "Perforated pseudomembranous colitis in the breast-fed infant." J Pediatr Surg 27 (1992): 744-6
View all 47 references
Moderate

Ceftriaxone (Includes Ceftriaxone/lidocaine) ↔ Gallbladder Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease, Gallbladder Disease, Biliary Obstruction

Ceftriaxone can precipitate in the gallbladder. Sonographic abnormalities and symptoms of gallbladder disease have been reported. Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver. Serial abdominal ultrasonography may be appropriate during therapy. The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.

References

  1. Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991): 1251-4
  2. Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988): 858
  3. Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992): 329-30
View all 7 references
Moderate

Ceftriaxone (Includes Ceftriaxone/lidocaine) ↔ Renal/Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease, Renal Dysfunction, Biliary Obstruction

Ceftriaxone is eliminated by both renal and hepatobiliary excretion. At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment. However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs. In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.

References

  1. Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984): 26-32
  2. Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988): 261-6
  3. Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982): 816-23
View all 15 references
Moderate

Cephalosporins (Includes Ceftriaxone/lidocaine) ↔ Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Cases of hepatitis have been reported with the use of certain cephalosporins. Transient rise in SGOT, SGPT, and alkaline phosphatase levels have also been observed. Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.

Moderate

Cephalosporins (Includes Ceftriaxone/lidocaine) ↔ Seizure Disorders

Moderate Potential Hazard, Moderate plausibility

Applies to: Seizures

Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures occur with drug therapy, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated. Monitor patients with preexisting seizure disorders.

ceftriaxone / lidocaine drug Interactions

There are 290 drug interactions with ceftriaxone / lidocaine

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide